Director Storms: Aehr Test Systems’ Board Loses 70k+ Shares as Insider Sales Surge, Questioning Growth Credibility

Insider Selling at Aehr Test Systems: What It Means for Investors

Recent Rule 144 filings show that director SLAYEN HOWARD T sold 6,819 shares of Aehr Test Systems common stock on May 13, 2026. The shares were sold at an average price of $104.73, leaving the director with roughly 169,709 shares. This transaction follows a pattern of frequent selling by Howard: from February through April 2026 he sold 1,800 shares (April 22), 25,000 shares (April 17), and 5,000 shares twice in early February. Over the past year, his cumulative sales exceed 70,000 shares, a sizable portion of his holding.

Investor Takeaway

The timing of Howard’s sale coincides with a sharp rise in the stock price—weekly gains of 2.2 % and a 35.7 % monthly upside—yet the market cap remains modest at $3.25 billion and the price‑earnings ratio is a steep ‑255, indicating the company is far from profitable. The sell‑off may signal that insiders are monetizing short‑term gains rather than betting on long‑term upside, which can dampen investor confidence. If other directors and executives continue to liquidate positions, the market could interpret this as a lack of conviction in the company’s growth trajectory.

Howard’s Profile and Historical Trading

Howard has been a long‑term director since 2025, and his trading record shows a consistent pattern of selling more than buying. His most recent purchase (9 July 2025) was a 9,253‑share buy, but since then he has sold more than 40,000 shares. The average sale price in 2026 has hovered around $80–$100, well above the 52‑week low of $8.31 and near the 52‑week high of $108.75. This suggests Howard may be capitalizing on the current price surge. His trades are executed via Rule 144, indicating they are likely “unrestricted” and not subject to lock‑up periods, further supporting the view that he is looking for liquidity.

Broader Insider Activity

The insider landscape is crowded: other senior figures—CFO Siu Chris, VP Sporck Alistair, and CEO Erickson Gayn—have also sold shares in the same week, collectively moving tens of thousands of shares. While the average sale price for the group aligns with Howard’s, the volume is significant. A concentrated wave of insider sales, coupled with the company’s negative P/E and high valuation multiples relative to earnings, could trigger a reassessment of the stock’s risk–reward profile by market participants.

Outlook

If Aehr’s earnings remain flat and the semiconductor equipment market continues to face headwinds, insider selling may persist as directors seek to lock in gains. For investors, this presents an opportunity to evaluate whether the current price truly reflects the company’s fundamentals or is inflated by temporary sentiment. Staying alert to future 4‑form filings will be essential—especially any shift from selling to buying—since that could signal a change in management’s confidence and potentially a turning point in the stock’s trajectory.